A biomarker for estimating no-reflow phenomenon in PCI-treated non-ST-segment elevation myocardial infarction patients: serum Cystatin C

Ömer Genç; Abdullah Yıldırım; Aslan Erdoğan

Article Details

A biomarker for estimating no-reflow phenomenon in PCI-treated non-ST-segment elevation myocardial infarction patients: serum Cystatin C

Authors:

Ömer Genç | Abdullah Yıldırım | Aslan Erdoğan

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Kardiyoloji

Journal:

Anatolian Current Medical Journal Vol.6 Issue 2, pp.108-115

Document Type:

Article

Publication Date:

8/2024

Document Language:

English

Document ID (Org No.):

2001312915

pISSN:

2718-0115

Keywords:

Abstract:

 Aims: Cystatin C Cys-C is a biochemical marker associated not only with renal function but also with inflammatory processes. We aimed to investigate the relationship between the post-percutaneous coronary intervention PCI no-reflow phenomenon NRP and Cys-C in patients with non-ST-segment elevation acute coronary syndrome NST-ACS. Methods: This retrospective, single-center observational study consecutively enrolled patients who were hospitalized with a diagnosis of NST-ACS and underwent PCI between October 2021 and February 2022. Baseline characteristics, medications, admission laboratory parameters, and angiographic features were recorded. Logistic regression and sensitivity analyses were performed to identify parameters associated with NRP. Results: Out of 199 patients mean age: 62.010.3, 59.8 male, 36 18.1 developed NRP. Patients who developed NRP had a lower ejection fraction 49.710.3 vs. 53.57.1, p0.046 and were less likely to be male 36.1 vs. 65.0, p0.001. Additionally, individuals with NRP exhibited higher blood urea and C-reactive protein levels than those without NRP p0.05 for both. Similarly, serum Cys-C levels were elevated in the former group 1.440.57 vs. 1.070.40 mgL, p0.001. Multivariable logistic regression analysis demonstrated that Cys-C odds ratio OR4.793, p0.014 and culprit lesion OR8.112, p0.043 for LCx, OR27.025, p0.001 for RCA were independently associated with NRP. Receiver operating characteristic curve analysis showed a cut-off point 1.1 mgL for Cys-C determined NRP with 72.2 sensitivity and 66.9 specificity area under the curve0.711, p0.001. Conclusion: We have demonstrated a potential association between the serum Cys-C level at admission and the occurrence of NRP among NST-ACS patients undergoing PCI.

 Aims: Cystatin C Cys-C is a biochemical marker associated not only with renal function but also with inflammatory processes. We aimed to investigate the relationship between the post-percutaneous coronary intervention PCI no-reflow phenomenon NRP and Cys-C in patients with non-ST-segment elevation acute coronary syndrome NST-ACS. Methods: This retrospective, single-center observational study consecutively enrolled patients who were hospitalized with a diagnosis of NST-ACS and underwent PCI between October 2021 and February 2022. Baseline characteristics, medications, admission laboratory parameters, and angiographic features were recorded. Logistic regression and sensitivity analyses were performed to identify parameters associated with NRP. Results: Out of 199 patients mean age: 62.010.3, 59.8 male, 36 18.1 developed NRP. Patients who developed NRP had a lower ejection fraction 49.710.3 vs. 53.57.1, p0.046 and were less likely to be male 36.1 vs. 65.0, p0.001. Additionally, individuals with NRP exhibited higher blood urea and C-reactive protein levels than those without NRP p0.05 for both. Similarly, serum Cys-C levels were elevated in the former group 1.440.57 vs. 1.070.40 mgL, p0.001. Multivariable logistic regression analysis demonstrated that Cys-C odds ratio OR4.793, p0.014 and culprit lesion OR8.112, p0.043 for LCx, OR27.025, p0.001 for RCA were independently associated with NRP. Receiver operating characteristic curve analysis showed a cut-off point 1.1 mgL for Cys-C determined NRP with 72.2 sensitivity and 66.9 specificity area under the curve0.711, p0.001. Conclusion: We have demonstrated a potential association between the serum Cys-C level at admission and the occurrence of NRP among NST-ACS patients undergoing PCI.

 Aims: Cystatin C Cys-C is a biochemical marker associated not only with renal function but also with inflammatory processes. We aimed to investigate the relationship between the post-percutaneous coronary intervention PCI no-reflow phenomenon NRP and Cys-C in patients with non-ST-segment elevation acute coronary syndrome NST-ACS. Methods: This retrospective, single-center observational study consecutively enrolled patients who were hospitalized with a diagnosis of NST-ACS and underwent PCI between October 2021 and February 2022. Baseline characteristics, medications, admission laboratory parameters, and angiographic features were recorded. Logistic regression and sensitivity analyses were performed to identify parameters associated with NRP. Results: Out of 199 patients mean age: 62.010.3, 59.8 male, 36 18.1 developed NRP. Patients who developed NRP had a lower ejection fraction 49.710.3 vs. 53.57.1, p0.046 and were less likely to be male 36.1 vs. 65.0, p0.001. Additionally, individuals with NRP exhibited higher blood urea and C-reactive protein levels than those without NRP p0.05 for both. Similarly, serum Cys-C levels were elevated in the former group 1.440.57 vs. 1.070.40 mgL, p0.001. Multivariable logistic regression analysis demonstrated that Cys-C odds ratio OR4.793, p0.014 and culprit lesion OR8.112, p0.043 for LCx, OR27.025, p0.001 for RCA were independently associated with NRP. Receiver operating characteristic curve analysis showed a cut-off point 1.1 mgL for Cys-C determined NRP with 72.2 sensitivity and 66.9 specificity area under the curve0.711, p0.001. Conclusion: We have demonstrated a potential association between the serum Cys-C level at admission and the occurrence of NRP among NST-ACS patients undergoing PCI.

 Aims: Cystatin C Cys-C is a biochemical marker associated not only with renal function but also with inflammatory processes. We aimed to investigate the relationship between the post-percutaneous coronary intervention PCI no-reflow phenomenon NRP and Cys-C in patients with non-ST-segment elevation acute coronary syndrome NST-ACS. Methods: This retrospective, single-center observational study consecutively enrolled patients who were hospitalized with a diagnosis of NST-ACS and underwent PCI between October 2021 and February 2022. Baseline characteristics, medications, admission laboratory parameters, and angiographic features were recorded. Logistic regression and sensitivity analyses were performed to identify parameters associated with NRP. Results: Out of 199 patients mean age: 62.010.3, 59.8 male, 36 18.1 developed NRP. Patients who developed NRP had a lower ejection fraction 49.710.3 vs. 53.57.1, p0.046 and were less likely to be male 36.1 vs. 65.0, p0.001. Additionally, individuals with NRP exhibited higher blood urea and C-reactive protein levels than those without NRP p0.05 for both. Similarly, serum Cys-C levels were elevated in the former group 1.440.57 vs. 1.070.40 mgL, p0.001. Multivariable logistic regression analysis demonstrated that Cys-C odds ratio OR4.793, p0.014 and culprit lesion OR8.112, p0.043 for LCx, OR27.025, p0.001 for RCA were independently associated with NRP. Receiver operating characteristic curve analysis showed a cut-off point 1.1 mgL for Cys-C determined NRP with 72.2 sensitivity and 66.9 specificity area under the curve0.711, p0.001. Conclusion: We have demonstrated a potential association between the serum Cys-C level at admission and the occurrence of NRP among NST-ACS patients undergoing PCI.

Article Details

A biomarker for estimating no-reflow phenomenon in PCI-treated non-ST-segment elevation myocardial infarction patients: serum Cystatin C

Authors: Ömer Genç | Abdullah Yıldırım | Aslan Erdoğan

Publisher: MediHealth Academy Yayıncılık

Main Topics: Kardiyoloji

Journal: Anatolian Current Medical Journal Vol.6 Issue 2, pp.108-115

Document Type: Article

Publication Date: 8/2024

Document Language: English

Document ID (Org No.): 2001312915

pISSN: 2718-0115

Cystatin C

no-reflow phenomenon

non-ST-segment elevation acute coronary syndrome

percutaneous coronary intervention

Issues

Authors:

Ömer Genç | Abdullah Yıldırım | Aslan Erdoğan

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Kardiyoloji

Journal:

Anatolian Current Medical Journal Vol.6 Issue 2, pp.108-115

Document Type:

Article

Publication Date:

8/2024

Document Language:

English

Document ID (Org No.):

2001312915

pISSN:

2718-0115